Sanofi-Aventis, Wellstat, Sign Licensing Deal for Potential Diabetes Drug

Wed, 10/21/2009 - 4:44am
NEW YORK (AP) — Sanofi-Aventis is paying privately-held Wellstat Therapeutics Corp. up to $350 million under terms of a licensing deal for a potential diabetes drug, the companies said Wednesday. Wellstat is developing PN2034 as a potential Type II diabetes treatment. The drug is in midstage development. Under the deal, Sanofi-Aventis will receive an exclusive worldwide license to develop, manufacture and market the drug candidate and related compounds. Gaithersburg, Md.-based Wellstat will receive an upfront cash payment and will be eligible to receive development and regulatory milestones from Paris-based Sanofi-Aventis, for total proceeds of as much as $350 million. Wellstat also will receive payments when certain commercial milestones are met, along with royalties on worldwide product sales.



Share this Story

You may login with either your assigned username or your e-mail address.
The password field is case sensitive.